Related Experiment Video
Updated: Jan 19, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies
Alessandro Allegra1, Vanessa Innao1, Andrea Gaetano Allegra1
1Division of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi," University of Messina, Messina, Italy.
Abstract:
The correct localization of molecules between nucleus and cytoplasm is fundamental for cellular homeostasis and is controlled by a bidirectional transport system. Exportin 1 (XPO1) regulates the passage of numerous cancer-related proteins. In this review, we summarize the development of a novel class of antitumor agents, known as selective inhibitors of nuclear export (SINEs). We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia. In the future, the numerous experimental studies currently underway will allow us to define the role of SINEs and will possibly permit these substances to be introduced into daily clinical practice.
Insights
Selective inhibitors of nuclear export (SINEs) are a novel class of antitumor agents targeting Exportin 1 (XPO1). These drugs show promise in treating various blood cancers, with ongoing studies to define their clinical role.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Cellular homeostasis relies on precise molecular localization between the nucleus and cytoplasm.
- Exportin 1 (XPO1) is a key regulator of nuclear-cytoplasmic transport for cancer-related proteins.
Purpose of the Study:
- To review the development and therapeutic potential of selective inhibitors of nuclear export (SINEs).
- To discuss the mechanism of action and clinical efficacy of SINEs in hematological malignancies.
Main Methods:
- Review of preclinical studies and clinical trials on SINEs.
- Analysis of SINEs' mechanism of action and effects on cancer cells.
Main Results:
- SINEs represent a promising new class of antitumor agents.
- Preclinical and clinical data indicate efficacy in multiple myeloma, lymphomas, and leukemias.
Conclusions:
- Selective inhibitors of nuclear export (SINEs) demonstrate significant therapeutic potential in various hematological cancers.
- Further research is expected to establish the role of SINEs in routine clinical practice for cancer treatment.
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Nuclear Protein Sorting
Proteins targeted to the nucleus carry nuclear localization signals or NLS recognized by import receptors in the cytosol. Similarly, proteins with nuclear export signals are recognized by export receptors. Import and export receptors are...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Nuclear Export of mRNA
Nuclear Export of mRNA
Regulation of Nuclear Protein Sorting

